Skip to content

Myriad Genetics MYGN Asset write-downs

Asset write-downs at other companies

GeneDx Holdings logo
GeneDx HoldingsWGS

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's asset write-downs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's asset write-downs?
Myriad Genetics (MYGN) reported asset write-downs of $5.4M in Q1 2026.